A delay ≥8 weeks to neoadjuvant chemotherapy before radical cystectomy increases the risk of upstaging

Bladder cancer is the fifth most common cancer in the United States with an estimated incidence of 81,190 in 2018 [1]. Approximately 25% of new cases present as muscle invasive disease, which is associated with a higher risk of developing metastasis and death. Studies have suggested that a delay in radical cystectomy (RC) is associated with a decrease in overall survival (OS) [2 –5] and it is now recommended to perform radical surgery within 3 months from diagnosis [6]. However, after RC, the 5-year survival is only 50% [7].

Source: Urologic Oncology: Seminars and Original Investigations - November 30, 2018 Category: Urology & Nephrology Authors: Fran çois Audenet, John P. Sfakianos, Nikhil Waingankar, Nora H. Ruel, Matthew D. Galsky, Bertram E. Yuh, Greg E. Gin Tags: Original article Source Type: research